Comprehensive analysis of necroptosis-related lncRNA signature with potential implications in tumor heterogeneity and prediction of prognosis in clear cell renal cell carcinoma

被引:4
作者
Lin, Hang [1 ]
Qu, Lingzhi [1 ]
Chen, Guanqiu [2 ]
Zhang, Chunfang [3 ]
Lu, Liqing [1 ,3 ]
Chen, Yongheng [1 ]
机构
[1] Cent South Univ, Xiangya Hosp, Dept Oncol, NHC Key Lab Canc Prote, Changsha, Peoples R China
[2] Xi An Jiao Tong Univ, Dept Urol, Affiliated Hosp 1, Xian, Peoples R China
[3] Cent South Univ, Xiangya Hosp, Dept Thorac Surg, Changsha, Peoples R China
基金
中国国家自然科学基金;
关键词
Necroptosis-related lncRNA; Clear cell renal cell carcinoma; Tumor heterogeneity; Prognosis; LONG NONCODING RNA; CANCER; PROMOTES; PROGRESSION; THERAPY; EXPRESSION;
D O I
10.1186/s40001-023-01194-4
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
BackgroundNecroptosis has been reported to play a critical role in occurrence and progression of cancer. The dysregulation of long non-coding RNAs (lncRNAs) is associated with the progression and metastasis of clear cell renal cell carcinoma (CCRCC). However, research on necroptosis-related lncRNAs in the tumor heterogeneity and prognosis of CCRCC is not completely unclear. This study aimed to analysis the tumor heterogeneity among CCRCC subgroups and construct a CCRCC prognostic signature based on necroptosis-related lncRNAs.MethodsWeighted gene co-expression network analysis (WGCNA) was performed to identify necroptosis-related lncRNAs. A preliminary classification of molecular subgroups was performed by non-negative matrix factorization (NMF) consensus clustering analysis. Comprehensive analyses, including fraction genome altered (FGA), tumor mutational burden (TMB), DNA methylation alterations, copy number variations (CNVs), and single nucleotide polymorphisms (SNPs), were performed to explore the potential factors for tumor heterogeneity among the three subgroups. Subsequently, we constructed a predictive signature by multivariate Cox regression. Nomogram, calibration curves, decision curve analysis (DCA), and time-dependent receiver-operating characteristics (ROC) were used to validate and evaluate the signature. Finally, immune correlation analyses, including immune-related signaling pathways, immune cell infiltration status and immune checkpoint gene expression level, were also performed.ResultsSeven necroptosis-related lncRNAs were screened out by WGCNA, and three subgroups were classified by NMF consensus clustering analysis. There were significant differences in survival prognosis, clinicopathological characteristics, enrichments of immune-related signaling pathway, degree of immune cell infiltration, and expression of immune checkpoint genes in the various subgroups. Most importantly, we found that 26 differentially expressed genes (DEGs) among the 3 subgroups were not affected by DNA methylation alterations, CNVs and SNPs. On the contrary, these DEGs were associated with the seven necroptosis-related lncRNAs. Subsequently, the identified RP11-133F8.2 and RP11-283G6.4 by multivariate Cox regression analysis were involved in the risk model, which could serve as an independent prognostic factor for CCRCC. Finally, qRT-PCR confirmed the differential expression of the two lncRNAs.ConclusionsThese findings contributed to understanding the function of necroptosis-related lncRNAs in CCRCC and provided new insights of prognostic evaluation and optimal therapeutic strategy for CCRCC.
引用
收藏
页数:15
相关论文
共 40 条
[1]   Treatment of renal cell carcinoma: Current status and future directions [J].
Barata, Pedro C. ;
Rini, Brian I. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (06) :507-524
[2]   Long Noncoding RNA and Cancer: A New Paradigm [J].
Bhan, Arunoday ;
Soleimani, Milad ;
Mandal, Subhrangsu S. .
CANCER RESEARCH, 2017, 77 (15) :3965-3981
[3]   Metagenes and molecular pattern discovery using matrix factorization [J].
Brunet, JP ;
Tamayo, P ;
Golub, TR ;
Mesirov, JP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (12) :4164-4169
[4]   Systemic Therapy for Metastatic Renal-Cell Carcinoma [J].
Choueiri, Toni K. ;
Motzer, Robert J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (04) :354-366
[5]   Necroptosis as an alternative form of programmed cell death [J].
Christofferson, Dana E. ;
Yuan, Junying .
CURRENT OPINION IN CELL BIOLOGY, 2010, 22 (02) :263-268
[6]   Identification and function of long non-coding RNA [J].
Emst, Carl ;
Morton, Cynthia C. .
FRONTIERS IN CELLULAR NEUROSCIENCE, 2013, 7
[7]   Renal cell cancer: overview of the current therapeutic landscape [J].
Erman, Mustafa ;
Benekli, Mustafa ;
Basaran, Mert ;
Bavbek, Sevil ;
Buyukberber, Suleyman ;
Coskun, Ugur ;
Demir, Gokhan ;
Karabulut, Bulent ;
Oksuzoglu, Berna ;
Ozkan, Metin ;
Sevinc, Alper ;
Yalcin, Suayib .
EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (09) :955-968
[8]   Developments in personalized therapy for metastatic renal cell carcinoma [J].
Fujiwara, Ryo ;
Kageyama, Susumu ;
Yuasa, Takeshi .
EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (06) :647-655
[9]   Absence of RIPK3 predicts necroptosis resistance in malignant melanoma [J].
Geserick, P. ;
Wang, J. ;
Schilling, R. ;
Horn, S. ;
Harris, P. A. ;
Bertin, J. ;
Gough, P. J. ;
Feoktistova, M. ;
Leverkus, M. .
CELL DEATH & DISEASE, 2015, 6 :e1884-e1884
[10]   The role of necroptosis in cancer biology and therapy [J].
Gong, Yitao ;
Fan, Zhiyao ;
Luo, Guopei ;
Yang, Chao ;
Huang, Qiuyi ;
Fan, Kun ;
Cheng, He ;
Jin, Kaizhou ;
Ni, Quanxing ;
YU, Xianjun ;
Liu, Chen .
MOLECULAR CANCER, 2019, 18 (1)